Bumetanide
Brand name: Bumetanide
Rank #331 of 500 drugs by total cost
$32.4M
Total Cost
735,077
Total Claims
$32.4M
Total Cost
22,315
Prescribers
$44
Cost per Claim
122,522
Beneficiaries
1,262,226
30-Day Fills
$1,451
Avg Cost/Provider
33
Avg Claims/Provider
About Bumetanide
Bumetanide (sold as Bumetanide) was prescribed 735,077 times by 22,315 Medicare Part D providers in 2023, costing the program $32.4M. At $44 per claim, this is a relatively affordable medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 328 | Mavacamten (Camzyos) | $32.8M | 3,969 |
| 329 | Empagliflozin/Linagliptin (Glyxambi) | $32.6M | 34,331 |
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
| 331 | Bumetanide (Bumetanide) | $32.4M | 735,077 |
| 332 | Voxelotor (Oxbryta) | $31.5M | 2,707 |
| 333 | Rivastigmine (Rivastigmine) | $31.4M | 118,567 |
| 334 | Zolpidem Tartrate (Zolpidem Tartrate) | $31.3M | 3,144,599 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology